Ischemix

Focus: Ischemix is a small-molecule biotechnology company focused on cardiovascular therapeutics, headquartered in Grafton, MA. The company operates at an early clinical stage with a focused pipeline in acute coronary syndromes and stable coronary artery disease.

Cardiovascular

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Ischemix

AI assessmentNot Hiring

No open roles listed right now. Follow Ischemix to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

CMX-2043

Stable Coronary Artery Disease

Phase 2

Clinical Trials (1)

NCT00984802Safety and Efficacy of CMX-2043 in Subjects Undergoing Coronary Reperfusion Therapy

Phase 2

Help build intelligence for Ischemix

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work on first-in-class or best-in-class small molecules for high-unmet-need cardiovascular indications with Phase 2 data in Non-STEMI and stable CAD
Focused pipeline and smaller team structure enable direct visibility into clinical development strategy and faster decision-making cycles
Early-stage company positioning offers equity upside potential if CMX-2043 advances successfully through Phase 3

Watch Out For

Zero active job openings reported; hiring posture is unclear and company appears to be in pre-growth or consolidation phase
Extremely limited public information on financials, funding, employee count, and company stage creates uncertainty around stability and growth trajectory
Only 2 clinical programs in Phase 2 with no Phase 3 catalysts visible—limited near-term validation milestones to drive career momentum

Generated by Claude from Ischemix's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

CMX-2043

Non STEMI

Phase 2

Clinical Trials (1)

NCT02103959Safety and Efficacy of CMX-2043 for Protection of the Heart and Kidneys in Subjects Undergoing Coronary Angiography

Phase 2

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Top TAs: Cardiovascular

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Cardiovascular

1 pipeline

Marketed

Pipeline